CA
ANIK icon

CSM Advisors’s Anika Therapeutics ANIK Stock Holding History

CSM Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$357K – 128
2021
Q4 		$357K Hold
10,000
– – 0.02% 147
2021
Q3 		$425K Hold
10,000
– – 0.03% 135
2021
Q2 		$433K Sell
10,000
-1,800
-15% -$76.7K 0.03% 140
2021
Q1 		$481K Buy
+11,800
New +$448K 0.07% 84

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

CSM Advisors's ANIK Position: Q1 2022 in Review

CSM Advisors sold out of Anika Therapeutics (ANIK) in Q1 2022, closing a stake of 10,000 shares — an estimated $357K sold.

CSM Advisors first reported a position in ANIK in Q1 2021 and held it in 4 quarters. The position peaked at $481K in Q1 2021. 118 funds tracked by Wall St. Rank hold ANIK as of Q1 2022.

  • CSM Advisors reported no remaining Anika Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CSM Advisors sold 10,000 Anika Therapeutics shares in Q1 2022, an estimated $357K.
  • CSM Advisors first reported a position in Anika Therapeutics in Q1 2021 and held it in 4 quarters.
  • CSM Advisors's Anika Therapeutics position peaked at $481K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2022.

Based on CSM Advisors's 13F filing for Q1 2022, filed 16 May 2022.